JP2013514074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514074A5 JP2013514074A5 JP2012543894A JP2012543894A JP2013514074A5 JP 2013514074 A5 JP2013514074 A5 JP 2013514074A5 JP 2012543894 A JP2012543894 A JP 2012543894A JP 2012543894 A JP2012543894 A JP 2012543894A JP 2013514074 A5 JP2013514074 A5 JP 2013514074A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- target protein
- variant
- prelp
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 35
- 102000004169 proteins and genes Human genes 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 22
- 238000000034 method Methods 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 18
- 101000611663 Homo sapiens Prolargin Proteins 0.000 claims 15
- 102100040659 Prolargin Human genes 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 15
- 210000001519 tissue Anatomy 0.000 claims 7
- 230000004071 biological effect Effects 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 239000012830 cancer therapeutic Substances 0.000 claims 5
- 238000012216 screening Methods 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 230000010190 G1 phase Effects 0.000 claims 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 230000004049 epigenetic modification Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000005740 tumor formation Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0922085.6 | 2009-12-17 | ||
| GBGB0922085.6A GB0922085D0 (en) | 2009-12-17 | 2009-12-17 | Cancer diagnosis and treatment |
| PCT/GB2010/002294 WO2011073629A2 (en) | 2009-12-17 | 2010-12-17 | Cancer diagnosis and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013514074A JP2013514074A (ja) | 2013-04-25 |
| JP2013514074A5 true JP2013514074A5 (https=) | 2014-02-13 |
Family
ID=41717134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543894A Pending JP2013514074A (ja) | 2009-12-17 | 2010-12-17 | 癌の診断および処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120304318A1 (https=) |
| EP (1) | EP2512601A2 (https=) |
| JP (1) | JP2013514074A (https=) |
| GB (1) | GB0922085D0 (https=) |
| WO (1) | WO2011073629A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| AU2009253675A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| US10513737B2 (en) | 2011-12-13 | 2019-12-24 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| KR101445560B1 (ko) | 2012-05-10 | 2014-09-29 | 한국수력원자력 주식회사 | 저준위 전리방사선에 민감한 유전자 검출 방법 및 상기 방법으로 검출된 유전자 |
| KR101416147B1 (ko) * | 2012-07-18 | 2014-07-09 | 국립암센터 | 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도 |
| EP2885640B1 (en) | 2012-08-16 | 2018-07-18 | Genomedx Biosciences, Inc. | Prostate cancer prognostics using biomarkers |
| US20160032395A1 (en) * | 2013-03-14 | 2016-02-04 | Elai Davicioni | Cancer biomarkers and classifiers and uses thereof |
| EP4115891A1 (en) | 2016-08-05 | 2023-01-11 | The Research Foundation for The State University of New York | Keratin 17 as a biomarker for bladder cancer |
| EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| WO2018132916A1 (en) | 2017-01-20 | 2018-07-26 | Genomedx Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| CA3055925A1 (en) | 2017-03-09 | 2018-09-13 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| AU2018266733A1 (en) | 2017-05-12 | 2020-01-16 | Veracyte, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
| WO2019028285A2 (en) | 2017-08-04 | 2019-02-07 | Genomedx, Inc. | USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY |
| JP2021128140A (ja) * | 2020-06-30 | 2021-09-02 | 株式会社ヤマト | 漏水監視システム |
| CN113957152A (zh) * | 2021-12-14 | 2022-01-21 | 浙江大学 | 一种snhg6基因的检测试剂盒及其应用 |
| CN114592007B (zh) * | 2022-04-29 | 2023-10-27 | 昆明理工大学 | Far1基因的新用途 |
| GB202415229D0 (en) * | 2024-10-16 | 2024-11-27 | Ucl Business Ltd | Novel therapy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| EP0636186B1 (en) | 1992-04-03 | 1998-11-25 | The Perkin-Elmer Corporation | Probe composition and method |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| FI954316A7 (fi) | 1993-03-15 | 1995-11-03 | Cell Genesys Inc | Menetelmä DNA-vajauksen määrittämiseksi |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| US5552277A (en) | 1994-07-19 | 1996-09-03 | The Johns Hopkins University School Of Medicine | Genetic diagnosis of prostate cancer |
| WO1997027317A1 (en) | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU9484398A (en) * | 1997-09-17 | 1999-04-05 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| MXPA01002546A (es) * | 1998-09-14 | 2004-06-11 | Genentech Inc | Promocion o inibhicion de angiogenesis y cardiovascularizacion. |
| AU2003256701A1 (en) * | 2002-07-24 | 2004-02-09 | Schering Corporation | Methods of modulating proliferative conditions |
| GB0224436D0 (en) | 2002-10-21 | 2002-11-27 | Univ Cambridge Tech | Polypetides methods and means |
| US7659062B2 (en) | 2003-06-03 | 2010-02-09 | The Board of Trustee of the University of Arkansas System | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
| DE102004042822A1 (de) * | 2004-08-31 | 2006-03-16 | Technische Universität Dresden | Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen |
| CN101175862A (zh) * | 2005-02-10 | 2008-05-07 | 肿瘤疗法科学股份有限公司 | 诊断膀胱癌的方法 |
| AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| ATE476529T1 (de) * | 2005-07-08 | 2010-08-15 | Siemens Healthcare Diagnostics | Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie |
| WO2007082352A1 (en) * | 2006-01-20 | 2007-07-26 | Child Health Research Institute Inc | Method of treatment, prophylaxis and diagnosis of pathologies of the bone |
| EP2180320A1 (en) | 2006-06-05 | 2010-04-28 | Shimadzu Corporation | Tumor marker and method for determination of the occurence of cancerous disease |
| AT504702A1 (de) | 2006-12-22 | 2008-07-15 | Arc Austrian Res Centers Gmbh | Set von tumormarkern |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| US7759542B2 (en) * | 2007-08-01 | 2010-07-20 | National Yang-Ming University | Glycine N-methyltransferase (GNMT) animal model and use thereof |
-
2009
- 2009-12-17 GB GBGB0922085.6A patent/GB0922085D0/en not_active Ceased
-
2010
- 2010-12-17 US US13/516,749 patent/US20120304318A1/en not_active Abandoned
- 2010-12-17 JP JP2012543894A patent/JP2013514074A/ja active Pending
- 2010-12-17 WO PCT/GB2010/002294 patent/WO2011073629A2/en not_active Ceased
- 2010-12-17 EP EP10803264A patent/EP2512601A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013514074A5 (https=) | ||
| Bahnassy et al. | Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease | |
| Okajima et al. | Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function | |
| ES2489840T3 (es) | Pronóstico molecular y clasificación de melanoma maligno en base a marcadores seleccionados entre la lista que consiste en RGS1, NCOA3, SPP1, PHIP | |
| JP2013127477A5 (https=) | ||
| JP2011517932A5 (https=) | ||
| Mohamed et al. | Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? | |
| JP2012500389A5 (https=) | ||
| KR20100072283A (ko) | 환자의 유전자-베이스 알고리즘적 암 예후 및 임상적 결과 | |
| JP2011516032A5 (https=) | ||
| Hu et al. | Hepatitis B virus X protein related lncRNA WEE2-AS1 promotes hepatocellular carcinoma proliferation and invasion | |
| ES2742840T3 (es) | Biomarcadores de micro-ARN para identificar el riesgo y/o diagnosticar tumor pulmonar | |
| TW201243331A (en) | Line-1 hypomethylation as a biomarker for early-onset colorectal cancer | |
| JP2019534321A5 (https=) | ||
| Tao et al. | Predicting the response of neoadjuvant therapy for patients with esophageal carcinoma: an in-depth literature review | |
| US20240084400A1 (en) | Methods for prognosing, diagnosing, and treating colorectal cancer | |
| KR20210040621A (ko) | 유방암 게놈 연구에서 검출된 마커를 사용한 유방암 진단용 키트 | |
| Mengual et al. | Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers | |
| Uemura et al. | Hypoxia-inducible adrenomedullin in colorectal cancer | |
| JP2024170603A (ja) | 免疫チェックポイント阻害療法からの利益を予測する方法 | |
| Osama et al. | Comparison between miR-199b-5p and AFP in the diagnosis of hepatitis C-associated hepatocellular carcinoma | |
| JP2014054198A (ja) | 大腸ガン検出方法、診断用キット及びｄｎａチップ | |
| CN103616518A (zh) | 一种miRNA分子作为肝癌预后的生物标记物的用途 | |
| Barnie et al. | Biomarkers in Colon Cancer Metastasis | |
| Oktay et al. | Diagnostic Value of Circulating miRNA-16-5p and miRNA-221-3p in Thyroid Cancer |